a2755c

6-K 1 a2755c.htm 1ST QUARTER RESULTS a2755c

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK delivers strong Q1 performance and start to 2026


Strong Specialty Medicines performance drives sales and core operating profit growth
●	Total Q1 sales £7.6 billion +2% AER; +5% CER
●	Specialty Medicines sales £3.2 billion (+14%); Respiratory, Immunology & Inflammation £0.9 billion (+16%); Oncology £0.5 billion (+28%); HIV sales £1.8 billion (+10%)
●	Vaccines sales £2.1 billion (+4%); Shingrix £1.0 billion (+20%); Meningitis vaccines £0.3 billion (-3%); and Arexvy £0.1 billion (-18%)
●	General Medicines sales £2.3 billion (-6%); Trelegy £0.6 billion (stable)
●	Total operating profit +9% and Total EPS +15% driven by Core operating profit growth and higher other income from disposals, partly offset by higher CCL charges
●	Core operating profit +10% and Core EPS +9% reflecting higher sales, favourable product and regional mix, SG&A benefits and higher royalty income, partly offset by increased investment in R&D and new asset launches.
●	Cash generated from operations of £1.4 billion with free cash flow of £0.8 billion

(Financial Performance – Q1 2026 results unless otherwise stated, growth % and commentary at CER as defined on page 42. In Q1 2026, the adverse currency impact on AER versus CER primarily reflected the strengthening of Sterling against the USD. See page 8 for further details.)

	Q1 2026
	£m	% AER	% CER
Turnover	7,629	2	5
Total operating profit	2,293	3	9
Total operating margin %	30.1%	0.6ppts	1.3ppts
Total EPS	43.2p	9	15
Core operating profit	2,650	5	10
Core operating margin %	34.7%	1.0ppts	1.8ppts
Core EPS	46.5p	4	9
Cash generated from operations	1,350	4


Pipeline progress and R&D acceleration:

●	New product approvals for: Exdensur (EU & China for severe asthma with an eosinophilic phenotype and nasal polyps); Nucala COPD (EU); Blenrep (China for multiple myeloma)
●	Bepirovirsen, potential functional cure for chronic hepatitis B, regulatory filings accepted in US, EU, China and Japan. Data to be presented at EASL in Q2
●	Efimosfermin (FGF21) granted US Breakthrough and EU PRIME designations for liver disease MASH
●	Phase I data for Mo-Rez ADC in difficult-to-treat endometrial and ovarian cancer supports initiation of 5 phase III trials in 2026

SEC Form 6-K filed by GSK plc